Drug Approval | October 01, 2025
AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
cSCC is one of the most common cancers in the U.S. and globally
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Experts urge early detection & better access to care
ANVIMO will be available in dosages of 240 mg and 480 mg
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Subscribe To Our Newsletter & Stay Updated
